Oncogenesis
@oncogenesisnature.bsky.social
November 13, 2025 at 8:40 AM
Check how this study demonstrates that targeting KAT2A with a PROTAC degrader decreases MYCN activity and inhibits NB cell proliferation, which hold the potential to make a significant impact on the management of this aggressive childhood cancer.
November 13, 2025 at 8:40 AM
Check how this study demonstrates that targeting KAT2A with a PROTAC degrader decreases MYCN activity and inhibits NB cell proliferation, which hold the potential to make a significant impact on the management of this aggressive childhood cancer.
November 11, 2025 at 10:41 AM
Check how their findings reveal that targeting NFATc1 simultaneously restricts biosynthetic precursors and impairs cell cycle progression in CRC, suggesting that NFATc1 inhibition is a promising therapeutic strategy.
November 11, 2025 at 10:41 AM
Check how their findings reveal that targeting NFATc1 simultaneously restricts biosynthetic precursors and impairs cell cycle progression in CRC, suggesting that NFATc1 inhibition is a promising therapeutic strategy.
November 7, 2025 at 9:53 AM
Check how this study unveils the involvement of the EPHA5-STAT3 signaling pathway in Follicular Thyroid Cancer and how this discovery offers a promising new target for genetic intervention in the its treatment.
November 7, 2025 at 9:53 AM
Check how this study unveils the involvement of the EPHA5-STAT3 signaling pathway in Follicular Thyroid Cancer and how this discovery offers a promising new target for genetic intervention in the its treatment.
November 4, 2025 at 8:02 AM
Check how this study highlights LINC01432 as a potential therapeutic target for overcoming resistance in high-risk multiple myeloma.
November 4, 2025 at 8:02 AM
Check how this study highlights LINC01432 as a potential therapeutic target for overcoming resistance in high-risk multiple myeloma.
October 30, 2025 at 8:19 AM
Check how this study demonstrates that SYT7 functions as an oncoprotein in NPC, driving tumor progression through its regulation of ALDH1A3-mediated glycolysis and STAT3 signaling pathways, revealing its potential as a biomarker for the prediction and treatment of NPC.
October 30, 2025 at 8:19 AM
Check how this study demonstrates that SYT7 functions as an oncoprotein in NPC, driving tumor progression through its regulation of ALDH1A3-mediated glycolysis and STAT3 signaling pathways, revealing its potential as a biomarker for the prediction and treatment of NPC.
Special thanks to the Scientific Committee:
Laurent Le Cam, @fredericbost.bsky.social, Alice Carrier, Nathalie Mazure, @jer-06.bsky.social, Stéphane Rocchi, Rodrigue Rossignol, Jean-Emmanuel Sarry & Sophie Vasseur.
Laurent Le Cam, @fredericbost.bsky.social, Alice Carrier, Nathalie Mazure, @jer-06.bsky.social, Stéphane Rocchi, Rodrigue Rossignol, Jean-Emmanuel Sarry & Sophie Vasseur.
October 27, 2025 at 2:35 PM
Special thanks to the Scientific Committee:
Laurent Le Cam, @fredericbost.bsky.social, Alice Carrier, Nathalie Mazure, @jer-06.bsky.social, Stéphane Rocchi, Rodrigue Rossignol, Jean-Emmanuel Sarry & Sophie Vasseur.
Laurent Le Cam, @fredericbost.bsky.social, Alice Carrier, Nathalie Mazure, @jer-06.bsky.social, Stéphane Rocchi, Rodrigue Rossignol, Jean-Emmanuel Sarry & Sophie Vasseur.
📢 Coming soon: Oncogenesis will publish a meeting report and launch a Special Issue on Metabolism and Cancer, featuring insights from 13 leading experts. Stay tuned! 👀
October 27, 2025 at 2:29 PM
📢 Coming soon: Oncogenesis will publish a meeting report and launch a Special Issue on Metabolism and Cancer, featuring insights from 13 leading experts. Stay tuned! 👀
We’re thrilled to continue supporting groundbreaking research in cancer metabolism and recognize early-career scientists shaping the future of oncology.
October 27, 2025 at 2:29 PM
We’re thrilled to continue supporting groundbreaking research in cancer metabolism and recognize early-career scientists shaping the future of oncology.
🏆 Springer Nature Oncogenesis Poster Prize
Congratulations to Maximilian Krämer (MSNZ, UKW) for his outstanding work:
“Metabolic Remodeling of Tumor-Draining Lymph Nodes During Disease Progression in Triple-Negative Breast Cancer.”
👏 Well deserved!
Congratulations to Maximilian Krämer (MSNZ, UKW) for his outstanding work:
“Metabolic Remodeling of Tumor-Draining Lymph Nodes During Disease Progression in Triple-Negative Breast Cancer.”
👏 Well deserved!
October 27, 2025 at 2:28 PM
🏆 Springer Nature Oncogenesis Poster Prize
Congratulations to Maximilian Krämer (MSNZ, UKW) for his outstanding work:
“Metabolic Remodeling of Tumor-Draining Lymph Nodes During Disease Progression in Triple-Negative Breast Cancer.”
👏 Well deserved!
Congratulations to Maximilian Krämer (MSNZ, UKW) for his outstanding work:
“Metabolic Remodeling of Tumor-Draining Lymph Nodes During Disease Progression in Triple-Negative Breast Cancer.”
👏 Well deserved!
Organized by Laurent LeCam (IRCM) and the Scientific Committee, the event gathered world experts including keynote speakers Marcia Haigis (Harvard), Emmanuelle Passegué (Columbia), and Matthew Vander Heiden (Koch Institute).
October 27, 2025 at 2:28 PM
Organized by Laurent LeCam (IRCM) and the Scientific Committee, the event gathered world experts including keynote speakers Marcia Haigis (Harvard), Emmanuelle Passegué (Columbia), and Matthew Vander Heiden (Koch Institute).
October 16, 2025 at 9:19 AM
Check the working model the author propose where HOTAIR serves as a scaffold enhancing the interaction between MEST and super-enhancers, increasing MEST expression, promoting glioblastoma cell proliferation and invasive migration, and ultimately contributing to tumor progression.
October 16, 2025 at 9:19 AM
Check the working model the author propose where HOTAIR serves as a scaffold enhancing the interaction between MEST and super-enhancers, increasing MEST expression, promoting glioblastoma cell proliferation and invasive migration, and ultimately contributing to tumor progression.
October 14, 2025 at 7:11 AM